148 related articles for article (PubMed ID: 10780529)
1. Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes.
Spierings DC; Agsteribbe E; Wilschut J; Huckriede A
Br J Cancer; 2000 Apr; 82(8):1474-9. PubMed ID: 10780529
[TBL] [Abstract][Full Text] [Related]
2. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.
Lorenzi S; Forloni M; Cifaldi L; Antonucci C; Citti A; Boldrini R; Pezzullo M; Castellano A; Russo V; van der Bruggen P; Giacomini P; Locatelli F; Fruci D
PLoS One; 2012; 7(10):e46928. PubMed ID: 23071666
[TBL] [Abstract][Full Text] [Related]
3. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells.
White CA; Thomson SA; Cooper L; van Endert PM; Tampe R; Coupar B; Qiu L; Parsons PG; Moss DJ; Khanna R
Int J Cancer; 1998 Feb; 75(4):590-5. PubMed ID: 9466661
[TBL] [Abstract][Full Text] [Related]
4. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes.
Vertuani S; De Geer A; Levitsky V; Kogner P; Kiessling R; Levitskaya J
Cancer Res; 2003 Nov; 63(22):8006-13. PubMed ID: 14633733
[TBL] [Abstract][Full Text] [Related]
5. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
6. Trypanosoma cruzi infection does not impair major histocompatibility complex class I presentation of antigen to cytotoxic T lymphocytes.
Buckner FS; Wipke BT; Van Voorhis WC
Eur J Immunol; 1997 Oct; 27(10):2541-8. PubMed ID: 9368608
[TBL] [Abstract][Full Text] [Related]
7. Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells.
Gopas J; Itzhaky D; Segev Y; Salzberg S; Trink B; Isakov N; Rager-Zisman B
Cancer Immunol Immunother; 1992; 34(5):313-20. PubMed ID: 1347254
[TBL] [Abstract][Full Text] [Related]
8. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
Ochsenbein AF; Sierro S; Odermatt B; Pericin M; Karrer U; Hermans J; Hemmi S; Hengartner H; Zinkernagel RM
Nature; 2001 Jun; 411(6841):1058-64. PubMed ID: 11429607
[TBL] [Abstract][Full Text] [Related]
9. Differential recruitment of viral and allo-epitopes into the MHC class I antigen processing pathway of a novel mutant of Ltk- cells. HSV/MHC class I restriction/immune recognition/antigen processing/antigen presentation/influenza virus.
Lippé R; Kolaitis G; Michaelis C; Tufaro F; Jefferies WA
J Immunol; 1993 Apr; 150(8 Pt 1):3170-9. PubMed ID: 7682234
[TBL] [Abstract][Full Text] [Related]
10. RPE cells resist bystander killing by CTLs, but are highly susceptible to antigen-dependent CTL killing.
Gregerson DS; Lew KL; McPherson SW; Heuss ND; Ferrington DA
Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5385-94. PubMed ID: 17122128
[TBL] [Abstract][Full Text] [Related]
11. IFN-gamma-induced recognition of the antigen-processing variant CMT.64 by cytolytic T cells can be replaced by sequential addition of beta 2 microglobulin and antigenic peptides.
Jefferies WA; Kolaitis G; Gabathuler R
J Immunol; 1993 Sep; 151(6):2974-85. PubMed ID: 8397249
[TBL] [Abstract][Full Text] [Related]
12. LMP2+ proteasomes are required for the presentation of specific antigens to cytotoxic T lymphocytes.
Sibille C; Gould KG; Willard-Gallo K; Thomson S; Rivett AJ; Powis S; Butcher GW; De Baetselier P
Curr Biol; 1995 Aug; 5(8):923-30. PubMed ID: 7583150
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocytes recognize and lyse chondrocytes under inflammatory, but not non-inflammatory conditions.
Cohen ES; Bodmer HC
Immunology; 2003 May; 109(1):8-14. PubMed ID: 12709012
[TBL] [Abstract][Full Text] [Related]
14. Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.
Melief CJ; Kast WM
Ciba Found Symp; 1994; 187():97-104; discussion 104-12. PubMed ID: 7796678
[TBL] [Abstract][Full Text] [Related]
15. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
[TBL] [Abstract][Full Text] [Related]
16. Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation.
Li Y; Ke Y; Gottlieb PD; Kapp JA
J Leukoc Biol; 1994 Nov; 56(5):616-24. PubMed ID: 7525819
[TBL] [Abstract][Full Text] [Related]
17. Identification of overlapping class I and class II H-2d-restricted T cell determinants of influenza virus N1 neuraminidase that require infectious virus for presentation.
Wysocka M; Eisenlohr LC; Otvos L; Horowitz D; Yewdell JW; Bennink JR; Hackett CJ
Virology; 1994 May; 201(1):86-94. PubMed ID: 7513927
[TBL] [Abstract][Full Text] [Related]
18. Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
Shamamian P; Mancini M; Kawakami Y; Restifo NP; Rosenberg SA; Topalian SL
Cancer Immunol Immunother; 1994 Aug; 39(2):73-83. PubMed ID: 7519127
[TBL] [Abstract][Full Text] [Related]
19. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D
Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
Croce M; Meazza R; Orengo AM; Fabbi M; Borghi M; Ribatti D; Nico B; Carlini B; Pistoia V; Corrias MV; Ferrini S
Cancer Immunol Immunother; 2008 Nov; 57(11):1625-34. PubMed ID: 18324400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
